← Back to Search

Device

TMS for Mild Cognitive Impairment (TMS-fMRI Trial)

Phase 2
Recruiting
Led By Ying-hui Chou, ScD
Research Sponsored by University of Arizona
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up immediately after and 24 hours after intervention
Awards & highlights

TMS-fMRI Trial Summary

This trial will test if a non-invasive brain stimulation, TBS, can improve learning and memory abilities in patients with Alzheimer's disease by measuring immediate changes in targeted brain activity, such as hippocampus activation, following each TBS session.

Who is the study for?
This trial is for individuals aged 50-80 with mild cognitive impairment, who can attend daily sessions on weekdays for one week. They must have certain scores on cognitive tests like the MMSE or MoCA, speak English, be right-handed, and not have dementia. People with other neurological disorders, contraindications to TMS or MRI, untreated depression, active cancer treatment or conditions affecting cognition cannot join.Check my eligibility
What is being tested?
The study is testing how repetitive Transcranial Magnetic Stimulation (rTMS), a non-invasive brain stimulation technique targeting the hippocampus using real-time MRI monitoring (interleaved TBS-MRI), affects brain function in those with mild cognitive impairment. It aims to understand if rTMS can improve memory by promoting synaptic plasticity.See study design
What are the potential side effects?
While specific side effects are not listed here, common side effects of rTMS may include headache or discomfort at the stimulation site. Real-time MRI monitoring minimizes risks but may involve typical MRI-related concerns such as reactions to contrast agents if used.

TMS-fMRI Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~immediately after and 24 hours after intervention
This trial's timeline: 3 weeks for screening, Varies for treatment, and immediately after and 24 hours after intervention for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Secondary outcome measures
Brain imaging data
Correction rate in memory association recall

TMS-fMRI Trial Design

2Treatment groups
Experimental Treatment
Group I: Sham TBS-Active TBSExperimental Treatment2 Interventions
Sham TBS in block one, Active TBS in block two
Group II: Active TBS-Sham TBSExperimental Treatment2 Interventions
Active TBS in block one, Sham TBS in block two
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Transcranial Magnetic Stimulation
2017
Completed Phase 4
~730

Find a Location

Who is running the clinical trial?

University of ArizonaLead Sponsor
514 Previous Clinical Trials
148,252 Total Patients Enrolled
National Institute on Aging (NIA)NIH
1,668 Previous Clinical Trials
28,005,045 Total Patients Enrolled
Ying-hui Chou, ScDPrincipal InvestigatorUniversity of Arizona

Media Library

Transcranial Magnetic Stimulation (Device) Clinical Trial Eligibility Overview. Trial Name: NCT05515952 — Phase 2
Mild Cognitive Impairment Research Study Groups: Active TBS-Sham TBS, Sham TBS-Active TBS
Mild Cognitive Impairment Clinical Trial 2023: Transcranial Magnetic Stimulation Highlights & Side Effects. Trial Name: NCT05515952 — Phase 2
Transcranial Magnetic Stimulation (Device) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05515952 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment open for the current clinical trial?

"This trial is seeking 38 volunteers aged 50-80 with mild cognitive impairment (MCI). To qualify for the study, participants must meet a range of criteria including: being right handed and English speaking; scoring between 24-27 on the Mini Mental State Exam or 18-26 on the Montreal Cognitive Assessment or having a Clinical Dementia Rating Scale score of 0.5; and not participating in another interventional study within 6 months prior to beginning this one. Additionally, they must be able to attend an intervention daily (Monday through Friday) over 4 days."

Answered by AI

Does this medical experiment accept participants who are over twenty years of age?

"This trial has set the eligibility age between 50 to 80, and there are 24 studies for participants below that threshold, as well as 535 for those above."

Answered by AI

Are there still opportunities to participate in this experiment?

"According to records hosted on clinicaltrials.gov, this medical trial is no longer recruiting patients as of October 2022. Although the study has ended its recruitment phase, there are still 572 other studies currently looking for participants."

Answered by AI

Who else is applying?

What state do they live in?
Pennsylvania
What portion of applicants met pre-screening criteria?
Did not meet criteria
How many prior treatments have patients received?
0
Recent research and studies
clinicaltrials.govStudy
Interleaved TMS-fMRI for Hippocampal Stimulation: Modeling Dose-Response Relationship in Amnestic Mild Cognitive Impairment
Ying-hui Chou 2022. "Interleaved TMS-fMRI for Hippocampal Stimulation: Modeling Dose-Response Relationship in Amnestic Mild Cognitive Impairment". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05515952.
All > Mild Cognitive Impairment
~8 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top